Key result
Long noncoding RNAs play pivotal roles in pancreatic cancer progression and have potential applications as diagnostic biomarkers and therapeutic targets.
Why the study?
The incidence of pancreatic cancer is increasing globally, highlighting the need to review the biological roles of long noncoding RNAs and their potential as biomarkers and therapeutic targets.
This review highlights the emerging role of long noncoding RNAs in the pathogenesis, diagnosis, and potential targeted therapy of pancreatic cancer.
Does not yet support lncRNA use in pancreatic cancer care; leaves open biomarker validation in prospective trials.
Long noncoding RNAs (lncRNAs) are noncoding RNA molecules with a heterogeneous structure consisting of 200 or more nucleotides. Because these noncoding RNAs are transcribed by RNA polymerase II, they have properties similar to messenger RNA (mRNA). Contrary to popular belief, the term "ncRNA" originated before the discovery of microRNAs. LncRNA genes are more numerous than protein-coding genes. They are the focus of current molecular research because of their pivotal roles in cancer-related processes such as cell proliferation, differentiation, and migration. The incidence of pancreatic cancer (PC) is increasing around the world and research on the molecular aspects of PC are growing. In this review, it is aimed to provide critical information about lncRNAs in PC, including the biological and oncological behaviors of lncRNAs in PC and their potential application in therapeutic strategies and as diagnostic tumor markers.
No takes yet. Share an insight, caveat, or question.
Güzel et al. (2023) conducted a review in Pancreatic cancer. Long noncoding RNAs (lncRNAs) was evaluated. Long noncoding RNAs play pivotal roles in pancreatic cancer progression and have potential applications as diagnostic biomarkers and therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: